Company: GEHC
Filing Date: 2025-12-02
Form Type: 424B2
Source: 0001193125-25-305442
Chunk: 8

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-12-02
Form: 424B2
Chunk 8
---
ad Medical Systems
(“Intelerad”), a leading provider of medical imaging software and digital enterprise workflow solutions, for a purchase price of approximately $2.3 billion in cash (the “Acquisition”). The transaction is expected to
close in the first half of 2026, subject to customary closing conditions and regulatory approvals set forth in the share purchase agreement dated November 20, 2025 (the “SPA”). The SPA also provides for certain termination rights
for both the Company and Intelerad.

The Financing

In connection with the Acquisition, we entered into a debt commitment letter with a syndicate of commercial banks (the “debt financing
sources”). Subject to the satisfaction of certain customary conditions, the debt financing sources committed to provide up to $1.0 billion in financing for the Acquisition, consisting of
a 364-day senior unsecured bridge loan facility (the “Bridge Facility”). Additionally, we plan to enter into a $750 million new senior unsecured delayed-draw term loan facility, with
substantially the same terms as our existing credit facilities, prior to consummation of the Acquisition (the “New Term Loan Facility”). We anticipate that the net proceeds from this offering, together with the New Term Loan Facility and
cash on hand, will be sufficient to fund the Acquisition, in which case we would not expect to borrow under the Bridge Facility.

S-1

This offering is not contingent upon the consummation of the Acquisition. However, if we do
not consummate the Acquisition on or prior to November 20, 2026, or if, on or prior to such date, the SPA is terminated, then we will be required to redeem each series of notes at a redemption price equal to 101% of the aggregate principal
amount of such notes, plus accrued and unpaid interest thereon, if any, to, but excluding, the Special Mandatory Redemption Date. The net proceeds from the offering of the notes will not be deposited into an escrow account pending any special
mandatory redemption of the notes. See “Description of Notes—Special Mandatory Redemption.”

S-2

THE OFFERING The following summary contains basic information about the notes and is not intended to be complete. It does not contain all the information that is important to you. For a more complete understanding of the notes, please refer to “Description of Notes.” As used in this section, the terms “us,” “we” and “our” refer only to GE HealthCare Technologies Inc. and not to any